Should You Buy Voyager Therapeutics Inc (VYGR) in Biotechnology Industry? – InvestorsObserver

Voyager Therapeutics Inc (VYGR) is around the bottom of the Biotechnology industry according to InvestorsObserver. VYGR received an overall rating of 33, which means that it scores higher than 33 percent of all stocks. Voyager Therapeutics Inc also achieved a score of 22 in the Biotechnology industry, putting it above 22 percent of Biotechnology stocks. Biotechnology is ranked 30 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Voyager Therapeutics Inc (VYGR) stock is lower by -4.86% while the S&P 500 is higher by 0.17% as of 11:15 AM on Thursday, Dec 24. VYGR has fallen -$0.41 from the previous closing price of $8.44 on volume of 324,546 shares. Over the past year the S&P 500 has gained 14.09% while VYGR has fallen -43.41%. VYGR earned $1.04 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 7.72.

Click Here to get the full Stock Score Report on Voyager Therapeutics Inc (VYGR) Stock.

View original post here:
Should You Buy Voyager Therapeutics Inc (VYGR) in Biotechnology Industry? - InvestorsObserver

Watch every SpaceX launch from 2020 and say Auld Lang Syne with fire – CNET

SpaceX aimed for up to 39 launches in 2020. The company wound up with 26, which still makes it the most prolific year for Elon Musk and his team, and second only to China and its Long March family of rockets with an unofficial count of 30.

Most notably, SpaceX's number includes two missions that carried astronauts to the International Space Station aboard a Crew Dragon, setting a number of milestones for human spaceflight. The Demo 2 mission that took NASA's Bob Behnken and Doug Hurley to the space station was the first crewed commercial flight and the first from US soil since the end of the space shuttle program in 2011. SpaceX did it again with four astronauts, including one from Japan's space agency, JAXA, on the Crew-1 mission in November.

From the lab to your inbox. Get the latest science stories from CNET every week.

The 14 Starlink satellite launches made up more than half the SpaceX flights this year, brought the broadband constellation closer to its first 1,000 flying routers in orbit and enabled the Better Than Nothingbeta to begin in October.

In addition to those 26 Falcon 9 flights, SpaceX also continued development of its next-generation Starship rocket at its south Texas facility. This culminated in the dramatic first high-altitude flight of a prototype, which was deemed a success despite the hard, explosive landing after reaching about 8 miles (12.5 kilometers) in altitude.

In 2021 we can expect even more of the same, with scheduled Falcon 9 missions carrying Starlinks, bigger satellites and more astronauts to space. There are even a few Falcon Heavy launches on the calendar, which we didn't get to see in 2020. And certainly we'll be seeing more from the Starship development team in Texas.

Meanwhile, sit back and enjoy every launch Elon and his pals brought us during what was otherwise a year we'd rather forget.

View original post here:

Watch every SpaceX launch from 2020 and say Auld Lang Syne with fire - CNET

Is Aquestive Therapeutics Inc (AQST) The Right Choice in Biotechnology? – InvestorsObserver

The 53 rating InvestorsObserver gives to Aquestive Therapeutics Inc (AQST) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 62 percent of stocks in the Biotechnology industry, AQSTs 53 overall rating means the stock scores better than 53 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Aquestive Therapeutics Inc (AQST) stock has fallen -5.9% while the S&P 500 has risen 0.17% as of 11:15 AM on Thursday, Dec 24. AQST has fallen -$0.39 from the previous closing price of $6.68 on volume of 289,118 shares. Over the past year the S&P 500 has risen 14.09% while AQST has risen 3.11%. AQST lost -$1.53 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Aquestive Therapeutics Inc (AQST) Stock.

Continue reading here:
Is Aquestive Therapeutics Inc (AQST) The Right Choice in Biotechnology? - InvestorsObserver

Is Allakos Inc (ALLK) a Winner in the Biotechnology Industry? – InvestorsObserver

The 66 rating InvestorsObserver gives to Allakos Inc (ALLK) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 82 percent of stocks in the Biotechnology industry, ALLKs 66 overall rating means the stock scores better than 66 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Allakos Inc (ALLK) stock has risen 0.58% while the S&P 500 has fallen -0.22% as of 3:25 PM on Tuesday, Dec 22. ALLK is higher by $0.84 from the previous closing price of $144.00 on volume of 295,894 shares. Over the past year the S&P 500 is up 14.35% while ALLK is higher by 41.36%. ALLK lost -$2.74 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Allakos Inc (ALLK) Stock.

Go here to see the original:
Is Allakos Inc (ALLK) a Winner in the Biotechnology Industry? - InvestorsObserver

Lockheed Martin buys Aerojet Rocketdyne to better compete with Musk’s SpaceX, Bezos’ Blue Origin – CNBC

The four RS-25 engines slated to fly on the maiden flight of NASA's SLS rocket, at the company's facility at NASA's Stennis Space Center.

Aerojet Rocketdyne

Lockheed Martin intends to buy Aerojet Rocketdyne at a $4.6 billion equity value, a deal that adds rocket engine and spacecraft propulsion assets to the defense contractor as it competes against the likes of Elon Musk's SpaceX and Jeff Bezos' Blue Origin in the growing space industry.

Aerojet Rocketdyne's business is split between defense and space, with about 60% of its sales to the former and 40% to the latter.

"Near term, the benefit for Lockheed Martin is on the defense side and then you're buying some optionality in the space markets down the road, to ideally get more competitive and defend your position," Canaccord Genuity analyst Ken Herbert told CNBC.

Lockheed Martin is Aerojet's largest customer, making up about 33% of its sales. United Launch Alliance, or ULA, makes up another 10% of Aerojet's sales a further complement to Lockheed Martin, which owns a 50% stake in ULA as a joint venture with Boeing.

"This is clearly a vertical integration play for [Lockheed Martin] and a larger investment on Space. The acquisition should complement their space launch business at United Launch Alliance, boost their capabilities in hypersonic propulsion and could have an impact on their battle field and tactical missile business," Bank of America analyst Ron Epstein wrote in a note to investors on Monday.

Herbert also pointed to the benefits of vertical integration as a catalyst for Lockheed Martin acquiring Aerojet Rocketdyne. While aerospace companies historically have wide networks of suppliers, Herbert pointed out that SpaceX and Blue Origin have had success with building as much as possible in-house to drive down costs.

"Maybe on the government side, [Lockheed Martin is thinking] that's where we need to be more vertically integrated to better compete over time against these companies coming into our market who are demonstrating real cost savings through their vertical integration," Herbert said.

Lockheed Martin recently highlighted SpaceX as a major competitor, shortly after the private company went toe-to-toe with ULA in the latest Pentagon award of billions in launch contracts.

"We have seen SpaceX as an emerging threat [and] they are more than an emerging threat right now," Lockheed Martin CFO Ken Possenriede said on the company's third quarter earnings conference call in October.

"But ... of the recent competitions we've had with them, we've actually been pleased with the outcome of where ULA landed relative to SpaceX," Possenriede added. "Going forward, we're confident that we certainly have the mission capable abilities, but we also think we now have a price point that is compelling to customers that will allow ULA to get its fair share of awards over SpaceX."

A Falcon 9 rocket launches the company's 14th Starlink mission on Oct. 18, 2020.

SpaceX

While Herbert expects Aerojet Rocketdyne's missile defense and hypersonic weapons programs will bring a boost, its space business has been on the sidelines of much of the grow in the space economy, as identified by CNBC PRO in November. The company's decreased lead in the space industry was exemplified in 2018, when long-time customer ULA picked Blue Origin's BE-4 engine over Aerojet's AR1 to power the coming Vulcan rocket.

But Lockheed Martin will add several key space products through Aerojet Rocketdyne, which builds the RS-25 engine for NASA's Space Launch System, the RL10C-X engine for the upper stage of ULA's Vulcan rocket, and small spacecraft control thrusters that are used by Boeing's Starliner crew capsules as well as NASA and ULA missions.

Jefferies analyst Greg Konrad noted the similarity of Lockheed Martin buying Aerojet Rocketdyne to Northrop Grumman's $7.8 billion acquisition of rocket maker Orbital ATK in 2018. Both deals represent a top defense contractor widening its reach by acquiring a company that specializes in rocket propulsion and space.

"We don't expect any issues with the deal closing. There will likely be a similar process as Northrop Grumman went through with Orbital ATK, with likely some pushback from key customers such as Raytheon and Boeing," Konrad wrote.

The deal is expected to close in the second half of 2021, with analysts highlighting regulatory approval as one of the top risks to the transaction. Read more analysis of Aerojet Rocketdyne's business here.

Subscribe to CNBC PRO for exclusive insights and analysis, and live business day programming from around the world.

Here is the original post:

Lockheed Martin buys Aerojet Rocketdyne to better compete with Musk's SpaceX, Bezos' Blue Origin - CNBC

Is Spero Therapeutics Inc (SPRO) a Winner in the Biotechnology Industry? – InvestorsObserver

Spero Therapeutics Inc (SPRO) is near the top in its industry group according to InvestorsObserver. SPRO gets an overall rating of 73. That means it scores higher than 73 percent of stocks. Spero Therapeutics Inc gets a 88 rank in the Biotechnology industry. Biotechnology is number 29 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Spero Therapeutics Inc (SPRO) stock has gained 17.83% while the S&P 500 is down -0.12% as of 10:24 AM on Tuesday, Dec 22. SPRO is up $3.39 from the previous closing price of $19.00 on volume of 235,658 shares. Over the past year the S&P 500 has risen 14.47% while SPRO is up 114.46%. SPRO lost -$4.21 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Spero Therapeutics Inc (SPRO) Stock.

Originally posted here:
Is Spero Therapeutics Inc (SPRO) a Winner in the Biotechnology Industry? - InvestorsObserver

SpaceX among Perry broadband project awards – pennlive.com

Three projects intended to increase the reach of broadband internet in Perry County over the next 10 years will include one by Elon Musks SpaceX company, according to the Federal Communications Commission.

The FCC on Dec. 7 announced the $9.2 billion award of money to companies around the country to increase broadband internet connectivity in rural communities. The money comes from fees that telecommunications customers pay. Pennsylvania as a whole is receiving $368.7 million in this round of awards to connect 327,000 rural customers.

In Perry County, three companies received more than $7.7 million to improve broadband to 4,200 homes and businesses, according to the FCCs Pennsylvania news release. The projects are designed to increase internet speeds to at least 100 megabits per second (Mbps) on download and 20 Mbps for uploads in unserved and underserved areas. However, a majority of projects would improve speeds to the gigabit levels, according to the FCC.

There was a strong and unified flow of comments from PA leadership and organizations to the FCC, encouraging the FCC to ensure that the auction process would give priority to unserved areas, instead of seeing the dollars simply flow to boosting speeds in areas that currently have service, said Nils Hagen-Frederiksen, press secretary for the Pennsylvania Public Utility Commission.

The winning companies and project scopes for Perry County are:

According to the telecom publication LightReading, Connect Everyone is a company attached to the next generation internet firm Starry, based in Boston and New York City.

Virginia Lam Abrams, a Starry spokesperson, confirmed in an email that Connect Everyone is a Starry Internet venture. However, due to FCC rules the company could not comment about the broadband projects at this time. More information could be available after January, she said. According to Starrys website, the company uses fixed wireless technology to expand broadband internet.

Space Exploration Technologies is a division of Musks SpaceX, the same Hawthorne, Calif., company working with NASA on new space-flight rockets. Musk is also the force behind the Tesla brand of electric cars. SpaceXs rural broadband projects are expected to use satellite technology.

Over the past couple years, SpaceX has been launching its Starlink satellites, which will create a network to expand broadband internet anywhere. There will eventually be thousands of satellites to create a seamless internet experience globally, according to SpaceX. The company began testing the new technology in October.

Windstream Services is a division of Windstream, the Little Rock, Ark.-based telecom company. It operates internet and other services in Pennsylvania. The LightReading story pointed to various technologies such as next generation DSL, fiber optic and wireless as potential for Windstreams projects.

Windstream also could not comment about the project due to FCC rules, said Scott Morris, a company spokesman.

Its not known when the projects would start, or what areas of the county would be served by the companies broadband solutions.

Jim T. Ryan can be reached via email at jtryan@perrycountytimes.com

Read more here:

SpaceX among Perry broadband project awards - pennlive.com

Is Stoke Therapeutics Inc (STOK) a Winner in the Biotechnology Industry? – InvestorsObserver

The 65 rating InvestorsObserver gives to Stoke Therapeutics Inc (STOK) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 79 percent of stocks in the Biotechnology industry, STOKs 65 overall rating means the stock scores better than 65 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Stoke Therapeutics Inc (STOK) stock is down -0.64% while the S&P 500 has risen 0.53% as of 2:32 PM on Wednesday, Dec 23. STOK has fallen -$0.38 from the previous closing price of $59.92 on volume of 143,445 shares. Over the past year the S&P 500 has gained 14.99% while STOK has risen 108.18%. STOK lost -$1.47 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Stoke Therapeutics Inc (STOK) Stock.

Link:
Is Stoke Therapeutics Inc (STOK) a Winner in the Biotechnology Industry? - InvestorsObserver

What’s Up in the Sky: Here’s what to expect in 2021 – Akron Beacon Journal

Suzie Dills| Special to Akron Beacon Journal

Although 2020 was a very difficult year for us, it gave us a chance to take time to observe astronomical highlights and night sky delights and view live broadcasts of historic launches. Many of us enjoyed the great conjunction of Jupiter and Saturn and the surprise visit of Comet NEOWISE. We watched the launch of the next Mars rover, Perseverance, in July. History was made with the NASA SpaceX Crew Dragon flight, the first American rocket launch since 2011 and the NASA SpaceX Crew-1 Mission.

Mars Mars 2020 Perseverance rover is scheduled to land inside the 28-mile Jezero Crater, on Feb. 18. Perseverance will search for signs of ancient life in Jezero Crater, which harbored a lake and river delta billions of years ago. The rover will collect and store samples for future return to Earth, along with demonstrating technology that could aid in future exploration. A tiny helicopter, namedIngenuity, hitched a ride on the belly of Perseverance. After the rover lands, it will find a place for Ingenuity to conduct test flights. Then Ingenuity will make a few short flights into the Martian skies. This will be the first ever flight by a rotorcraft on a planet beyond Earth.

SpaceX crew In May, the NASA SpaceX Crew-1 astronauts will return to Earth. Soon after the NASA SpaceX Crew-2 Mission with four astronauts aboard will head to the International Space Station. The Crew-2 astronauts will spend six months at the ISS.

Boeing crew Boeing Orbital Flight Test-2 is targeted to launch March 29. The first crewed mission for Boeings CST-100 Starlinerwill be slated for June or later.

Moon The first stage of the Artemis program for the return to the moonby humanswill begin with the launch of Artemis Iin November 2021. The mission is designed to test the crew spacecraft Orion and the Space Launch System. Crewed Artemis missions will follow.

Space telescope The James Webb Telescope is still on track for launch on Oct. 31. The James Webb Telescope will be the largest and most powerful space telescope ever built and launched into space. With the Webb, we will be able see much closer to the beginning of time, when the first stars and galaxies started to form.

March 10 The thin crescent moon joins Mercury, Jupiter and Saturn in the morning twilight.

April 25 Mercury and Venus will be about a degree apart, low in the western sky after sunset.

April 26 Supermoon: closest full moon of the year.

May 12 Venus and the thin crescent moon, less than 1 degree apart, low in the west-northwest at dusk.

May 26 Partial lunar eclipse, begins at 5:44 a.m. with the moon setting at 6:02 a.m.

June 10 Partial solar eclipse, will be underway with the sunrise at 5:52 am. Maximum at 5:55 a.m., and eclipse will end at 6:35 a.m.

July 11 The thin crescent moon will be 5 degrees from Venus and Mars, which will be separated by 1 degree low in the western sky at dusk.

Aug. 22 Seasonal blue moon, occurs when we have four full moonsin one season. The third is called the blue moon. This is the original definition of a blue moon.

Nov. 19 Near-total lunar eclipse. Partial eclipse begins at 2:18 a.m., maximum at 4:02 a.m. and eclipse ends at 5:47 a.m.

Dec. 5 Jupiter, Saturn, Venus and the moon form a spectacular line in the western sky after sunset.

Planets and moon:Jupiter and Saturn start the month low in the southwestern sky, right after sunset. By mid-month, they drop from view, but will return to the morning sky next month. Mercury returns to the evening sky in January and creates a spectacular trio with Jupiter and Saturn, in the southwest, right after sunset Jan. 10. Mercury will continue to climb higher and remains visible through the end of the month. Mercury reaches greatest elongation Jan. 23, 19 degrees east of the sun. Mars shines brightly overhead all month but continues to move away from Earth. At the beginning of the month, Mars is 84.3 million miles from Earth, at months end it will be 111 million miles away. Brilliant Venus will be low in the predawn southeastern at the beginning of January but lost in the suns glare at months end. Jan. 18-22 will be a great time to spot Uranus. Mars will pass north of Uranus, with Jan. 21 as the best night, when Uranus is 1.7 degreesdue south of Mars. On Jan. 1, Neptune will be 1 degree east of Phi Aquarii in eastern Aquarius. On Jan.14, the moon pairs with Mercury, 35 minutes after sunset. Then on Jan. 17 the moon passes south of Neptune and on Jan. 21 passes south of Mars and Uranus. In the predawn sky, the moon pairs with Venus on Jan. 11.

Constellations:East Great star hopping in this part of the sky! Start with the most magnificent picture in our stars, Orion, the Hunter. Look for the three stars in a line, which make up the belt of Orion. The bright red-orange star up and to the left of the belt is Betelgeuse. The bright blue-white star down and to the right of the belt is Rigel. Draw a line up from the belt to a red, orange star, Aldebaran, which is the eye of Taurus, the Bull. The sideways V shape is the face of Taurus. Above Taurus, the small cluster of stars is the Pleiades or Seven Sisters. Making a counterclockwise loop from the Pleiades, the next bright star is Capella. Continuing down, the two stars you see are Gemini, the Twins.

North The Big Dipper is beginning to swing up on its handle. Following the two stars at the end of the cup to the next bright star, is Polaris, or the North Star. The constellation Cassiopeia is above and to the left of Polaris and resembles the letter M.

West There you will see four stars that form the Great Square of Pegasus.

Binocular highlights When facing north, locate the M shape of Cassiopeia. From the left point of the M shape, scan slowly up to the left. You will see a fuzzy circular shape. That is the Andromeda Galaxy. It is 2.5 million light years away. From the right point of the M,scan up slightly. You will come upon the Double Cluster in Perseus. High overhead, you will see the small cluster of stars, the Pleiades or the Seven Sisters. ThePleiades is a beautiful open star cluster. Head to Orion, the Hunter. Scan below the three stars of Orions belt. You will see fuzzy area with bright stars. This is the Orion Nebula, a hydrogen gas cloud where new stars are forming.

The peak of the Quadrantid Meteor Shower is Jan. 3.

For further night sky details, maps and audio, visit my website http://www.starrytrails.com.

Visit the Hoover Price Planetarium: Visit http://www.mckinleymuseum.org, for limited show dates and times. Planetarium shows are free with museum admission. Seating is limited and will be on a first-come, first-served basis. The planetarium is located inside the McKinley Presidential Library & Museum, 800 McKinley Monument DriveNWin Canton. For more information,call the museum at 330-455-7043.

Read more here:

What's Up in the Sky: Here's what to expect in 2021 - Akron Beacon Journal

Is Allovir Inc (ALVR) the Top Pick in the Biotechnology Industry? – InvestorsObserver

Allovir Inc (ALVR) is near the middle in its industry group according to InvestorsObserver. ALVR gets an overall rating of 39. That means it scores higher than 39 percent of stocks. Allovir Inc gets a 39 rank in the Biotechnology industry. Biotechnology is number 32 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Allovir Inc (ALVR) stock is lower by -2.01% while the S&P 500 has gained 0.39% as of 10:45 AM on Wednesday, Dec 23. ALVR is down -$0.93 from the previous closing price of $45.97 on volume of 67,573 shares. Over the past year the S&P 500 is higher by 13.60% while ALVR is down -99.67%. ALVR lost -$0.44 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Allovir Inc (ALVR) Stock.

View original post here:
Is Allovir Inc (ALVR) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Is AIM ImmunoTech Inc (AIM) a Winner in the Biotechnology Industry? – InvestorsObserver

A rating of 12 puts AIM ImmunoTech Inc (AIM) near the bottom of the Biotechnology industry according to InvestorsObserver. AIM ImmunoTech Inc's score of 12 means it scores higher than 12% of stocks in the industry. AIM ImmunoTech Inc also received an overall rating of 20, putting it above 20% of all stocks. Biotechnology is ranked 32 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 20 would rank higher than 20 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

AIM ImmunoTech Inc (AIM) stock is lower by -2.91% while the S&P 500 has gained 0.39% as of 10:43 AM on Wednesday, Dec 23. AIM is down -$0.06 from the previous closing price of $2.06 on volume of 958,792 shares. Over the past year the S&P 500 has gained 14.83% while AIM has gained 308.16%. AIM lost -$0.44 per share the over the last 12 months.

Click Here to get the full Stock Score Report on AIM ImmunoTech Inc (AIM) Stock.

More here:
Is AIM ImmunoTech Inc (AIM) a Winner in the Biotechnology Industry? - InvestorsObserver

Where Does Anavex Life Sciences Corp (AVXL) Stock Fall in the Biotechnology Field? – InvestorsObserver

A rating of 96 puts Anavex Life Sciences Corp (AVXL) near the top of the Biotechnology industry according to InvestorsObserver. Anavex Life Sciences Corp's score of 96 means it scores higher than 96% of stocks in the industry. Anavex Life Sciences Corp also received an overall rating of 86, putting it above 86% of all stocks. Biotechnology is ranked 32 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Anavex Life Sciences Corp (AVXL) stock is down -2.26% while the S&P 500 is up 0.9% as of 10:41 AM on Monday, Dec 28. AVXL is lower by -$0.13 from the previous closing price of $5.75 on volume of 344,926 shares. Over the past year the S&P 500 is higher by 15.99% while AVXL is up 138.14%. AVXL lost -$0.43 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Anavex Life Sciences Corp (AVXL) Stock.

Read more:
Where Does Anavex Life Sciences Corp (AVXL) Stock Fall in the Biotechnology Field? - InvestorsObserver

RAYONT INC. – RAYT, Acquires Prema Life Pty Ltd and GGLG Properties Pty Ltd to Consolidate its Biotechnology and Health Care Portfolio. -…

Queensland, Australia, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Rayont Inc. (Rayont or the Company) (OTC PINK: RAYT), an expanding company focused on biotechnology, education and technology industries globally, today completed the acquisition of naturopathic and homeopathic manufacturer and distributor, Prema Life Pty Ltd (Prema Life). The Company also acquired 100% ownership of GGLG Properties Pty Ltd (GGLG) as trustee for (ATF) Gillard Property Trust, the property where Prema Life operates. Whilst this is a related party transaction, all relevant documents are being executed on an arms length basis and in keeping with all necessary legal and regulatory requirements.

Under the agreement Rayont Inc, through its wholly owned subsidiary Rayont (Australia) Pty Ltd, acquires 100% of the total outstanding shares and units of Prema Life, and GGLG in exchange for AU$1.5M (approximately US$1.1M) cash payable overseven installments within 180 days to Thealikasa (Australia) Pty Ltd who is the sole shareholder of record of Prema Life and GGLG, a major shareholder in Rayont Inc. The price is a 10% discount of the combined Net Tangible Asset value of both Companies.

In the event that Rayont Inc is unable to pay in cash, Thealikasa (Australia) Pty Ltd will accept shares based on a 20% discount of the average share price for the last 30 trading days from the December 22, 2020, that is USD 0.87 per share.

To comply with Australian foreign investment rules and regulations, Rayont (Australia) Pty Ltd is required to obtain written consent from the Australian Foreign Investment Review Board before the transfer of shares and units of GGLG Properties Pty Ltd (ATF) Gillard Property Trust.

Marshini Thulkanam, President and CEO of Rayont Inc stated, the acquisition of Prema Life and GGLG, in addition to our earlier investments in Next Generation Photo Dynamic Therapy (NGPDT) to treat cancer, enables Rayont to become one of the premiere one-stop nutraceutical biotechnology companies with research & development, manufacturing, distribution, education and support capabilities in Australia and the South East Asian region. With more than 20 years of trading history, Prema Life is positioned to increase revenue and profitability moving forward.

About Prema Life Pty Ltd

Prema Life is a HACCP certified manufacturer and supplier of functional foods and supplements, and of practitioner only naturopathic and homeopathic medicines. The Company produces an extensive range of products including proteins, green blends, sports nutrition, weight management and maintenance, and health and wellness products. Prema Life is well positioned through expanded contract manufacturing arrangements, direct to practitioner sales, over the counter sales via distributors, and through increased online sales of proprietary branded products.

The company hosts regular educational webinars and seminars for its extensive practitioners' network to learn about the products, which in turn facilitates sales to their customers.

Prema Life has been in alternative health products manufacturing, distribution and support for more than 20 years and has a total workforce of 22 people as of the day of the acquisition. Its revenues for the financial year ending June 30, 2020 were US$1,769,746, and a net loss of US$46,917 (based on todays exchange rate).

For more information: http://nva.com.au https://premalifeaustralia.comhttps://wonderfoods.com.au

About GGLG Properties Pty Ltd

GGLG is the owner and operator of 11 Aldinga Street, Brendale, Queensland, 4500, Australia. The facility has an area of 21,000 square feet with single floor buildings and is leased to Prema Life. The immediate plan is to build a double story building of 37,673 square feet for office, production and logistical support of Prema Life. The design and planning for this are in process at present.

The expanded facility will enable Prema Life to significantly increase production capacity and expand the scope of its product range and service offering in line with future growth strategies.

About Rayont Inc.

Rayont Inc. is a Nevada based company incorporated since 2011. As an expanding company, Rayont focuses on biotechnology, education and technology industries globally. The Company has made significant investments in the biotechnology and life sciences sectors by acquiring assets to operate cancer treatment technologies. In addition to having plans to grow its biotechnology portfolio by identifying, acquiring and integrating other assets within the healthcare area, the Company has investments in technology and education assets that offer remote education, artificial intelligence (AI), augmented reality (AR), remote learning solutions, end-to-end employee engagement platforms, and cloud-based platform technologies.

For further information, please visitwww.rayont.com

SAFE HARBOR

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Read more:
RAYONT INC. - RAYT, Acquires Prema Life Pty Ltd and GGLG Properties Pty Ltd to Consolidate its Biotechnology and Health Care Portfolio. -...

Where Does Akero Therapeutics Inc (AKRO) Stock Fall in the Biotechnology Field? – InvestorsObserver

The 62 rating InvestorsObserver gives to Akero Therapeutics Inc (AKRO) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 76 percent of stocks in the Biotechnology industry, AKROs 62 overall rating means the stock scores better than 62 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Akero Therapeutics Inc (AKRO) stock has gained 3.4% while the S&P 500 is lower by -0.22% as of 3:14 PM on Tuesday, Dec 22. AKRO has gained $0.87 from the previous closing price of $25.62 on volume of 255,146 shares. Over the past year the S&P 500 is higher by 14.35% while AKRO has gained 21.96%. AKRO lost -$2.16 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Akero Therapeutics Inc (AKRO) Stock.

Read the original:
Where Does Akero Therapeutics Inc (AKRO) Stock Fall in the Biotechnology Field? - InvestorsObserver

Is Voyager Therapeutics Inc (VYGR) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Voyager Therapeutics Inc (VYGR) is around the bottom of the Biotechnology industry according to InvestorsObserver. VYGR received an overall rating of 33, which means that it scores higher than 33 percent of all stocks. Voyager Therapeutics Inc also achieved a score of 22 in the Biotechnology industry, putting it above 22 percent of Biotechnology stocks. Biotechnology is ranked 32 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Voyager Therapeutics Inc (VYGR) stock is lower by -10.52% while the S&P 500 has gained 0.46% as of 9:56 AM on Wednesday, Dec 23. VYGR has fallen -$0.95 from the previous closing price of $9.03 on volume of 156,970 shares. Over the past year the S&P 500 has risen 14.92% while VYGR has fallen -46.06%. VYGR earned $1.04 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 7.77.

Click Here to get the full Stock Score Report on Voyager Therapeutics Inc (VYGR) Stock.

More here:
Is Voyager Therapeutics Inc (VYGR) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Maryland US Attorney’s Office Seizes Two Domain Names Purporting to be Websites of Biotechnology Companies Developing Treatments for Covid-19 – The…

Baltimore,Maryland The U.S. Attorneys Office for the District of Maryland has seized mordernatx.com and regeneronmedicals.com, which purported to be the websites of actual biotechnology companies developing treatments for the COVID-19 virus, but instead appears to have been used to collect the personal information of individuals visiting the sites, in order to use the information for nefarious purposes, including fraud, phishing attacks, and/or deployment of malware. Individuals visiting those sites now will see a message that the site has been seized by the federal government and be redirected to another site for additional information.

The seizure of the domain names was announced by United States Attorney for the District of Maryland Robert K. Hur and Special Agent in Charge John Eisert of Homeland Security Investigations Baltimore.

The U.S. Attorneys Office and our law enforcement partners are committed to bringing to justice the criminals that try to take advantage of this global pandemic to line their pockets at the expense of the most vulnerable, said U.S. Attorney Robert K. Hur. I urge citizens to remain vigilant. Dont provide personal information or click on websites or links contained in unsolicited e-mails. Dont become a victim.

These individuals took advantage of fear during the global pandemic and attempted to steal personal information for nefarious purposes, said HSI Baltimore Special Agent in Charge John Eisert. From the cyber realm to counterfeit medication to financial crime, Homeland Security Investigations is committed to detecting, investigating, and disrupting all types of fraud related to the COVID-19 pandemic.

According to the affidavits filed in support of these seizures, these investigations began in early December 2020, after corporate security for one of the companies located the spoof website and contacted HSIs Intellectual Property Rights Center (IPRC) and the HSI Cyber Crimes Center (C3). The other website was identified during an ongoing HSI C3 operation targeting malicious websites. The cases were referred to HSI Baltimore for investigation.

Specifically, on December 10, 2020, the Global Head of Corporate Security for a biotechnology company headquartered in Cambridge, Massachusetts, which has developed a COVID-19 vaccine that is awaiting approval by the U.S. Food and Drug Administration (FDA), contacted HSI IPRC and C3 by e-mail to report that the companys Cybersecurity Team had detected the domain name mordernatx.com, a fraudulent replication of the companys website. A review of that websites online content displayed the name and trademarked logos for the biotechnology company. As detailed in the affidavit, the logos, markings, colors, and text of the mordernatx.com webpage showed no substantive differences from the genuine company websites landing page, other than the fact that the fraudulent website had a slight misspelling of the companys name. However, individuals who clicked on the Contact Us tab, were redirected to an entry form requesting information such as name, company/institution, title, phone, e-mail, and comments/questions. Additional investigation revealed that the mordernatx.com domain name was registered on about December 8, 2020, through a company headquartered in Kuala Lumpur, Malaysia, with no personal information for the registrar listed.

The second domain name seized, regeneronmedicals.com, was identified on December 9, 2020, during an ongoing HSI C3 investigation targeting malicious websites. Investigators found that the subject domain name contained the name and trademarked logos of, and was visually similar to, the webpage of a biotechnology company headquartered in Westchester County, New York, which was granted an emergency use authorization by the FDA for an antibody cocktail used to treat COVID-19 in high-risk patients with mild to moderate COVID-19. Further investigation revealed that the subject domain name contained two e-mail addresses and a telephone number not found on the official company website. The phone number appeared to be a Voice over IP (VOIP) number. In addition, the Contact Us page on the regeneronmedicals.com site directed Healthcare professionals, patients or caregivers requesting specific product information, reporting an adverse event or reporting a product complaint to contact the Medical Department at the VOIP number. The same Contact Us tab also provided a link to submit medical inquiries which directed users to a page that was different from the corresponding page on the authentic website. Investigators also found that the subject domain name was registered on December 6, 2020, and lists the registrant as an individual residing in Onitsha Anambra, Nigeria.

By seizing these sites, the government has prevented third parties from acquiring the names and using them to commit additional crimes, as well as prevented third parties from continuing to access the sites in their present form.

Federal law enforcement agencies are united in our efforts to fight against COVID-19 fraud. HSI has identifiedtipsto recognize and report COVID-19 fraud. If you believe you are a victim of a fraud or attempted fraud involving COVID-19, you may also call the National Center for Disaster Fraud Hotline at 1-866-720-5721 or for more information e-mail justice.gov/coronavirus.

United States Attorney Robert K. Hur commended HSI for its work in these investigations. Mr. Hur thanked Assistant U.S. Attorneys Sean Delaney, Aaron S.J. Zelinsky, and Thomas M. Sullivan, who are handling these cases.

Like Loading...

Related

More here:
Maryland US Attorney's Office Seizes Two Domain Names Purporting to be Websites of Biotechnology Companies Developing Treatments for Covid-19 - The...

Global Bioinformatics Market Size And Future Prospective With Key Manufactures, Drivers & Trends 2019-2026||Agilent Technologies, Inc. (US),…

Bioinformatics Marketis expected to reach USD 26.33 billion by 2026 from USD 7.76 billion in 2018, at a CAGR of 16.5% in the forecast period 2019 to 2026. The new market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

To formulate the most excellent Bioinformatics market research report, an expert team follows several steps of collecting and analysing market data of the healthcare industry. Also, detailed market analysis has been performed here with the inputs from industry experts. Market definitions, segmentation, applications and value chain structure of the healthcare industry are all mentioned in the report. Businesses can acquire complete knowledge of general market conditions and tendencies with the information and data explained in this report. The credible Bioinformatics market report contains all the company profiles of the major players and brands.

Few of the major competitors currently working in the bioinformatics market areThermo Fisher Scientific (US), Illumina Inc. (US), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), BGI (China), Wuxi NextCODE (China), Eurofins Scientific (Luxembourg), Waters Corporation (US), Sophia Genetics (Switzerland), Partek (US), DNASTAR (US), Dassault Systmes (France), DNAnexus, Inc. (US), Genebio (Switzerland), ASEBIO (Spain), PerkinElmer Inc. (US), abm Inc.(Canada) a few among others.

Scope of the Bioinformatics Market

Bioinformatics market is segmented on the basis of countries into U.S., Canada, Mexico in North America, Brazil, Argentina, Rest of South America as a part of South America, Germany, France, U.K., Italy, Spain, Netherlands, Belgium, Russia, Turkey, Switzerland, Rest of Europe in Europe, China, Japan, India, Australia, Singapore, Thailand, Malaysia, South Korea, Indonesia, Philippines, Rest of Asia Pacific (APAC)as a part of Asia-Pacific (APAC), U.A.E, Egypt, Saudi Arabia, South Africa, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

To know more about the studyhttps://www.databridgemarketresearch.com/reports/global-bioinformatics-market

Market Drivers

Market Restraints

New Bioinformatics Market Development

Key Developments in the Market:

Enquire Here Get customization & check discount for report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bioinformatics-market

Report synopsis

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:Corporatesales@databridgemarketresearch.com

Link:
Global Bioinformatics Market Size And Future Prospective With Key Manufactures, Drivers & Trends 2019-2026||Agilent Technologies, Inc. (US),...

Global Gynecology Partnering Report 2020: Access Deals Signed Between the World’s Leading Pharmaceutical and Biotechnology Companies Since 2010 -…

DUBLIN, Dec. 23, 2020 /PRNewswire/ -- The "Global Gynecology Partnering 2010-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Global Gynecology Partnering 2010-2020: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals.

The report presents financial deal terms values for Gynecology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Gynecology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gynecology partnering and dealmaking since 2010.

The report includes deals for the following indications: Adenomyosis, Cervical Intraepithelial Neoplasia (CIN), Endometriosis, Fibroids, Human papillomavirus (HPV), Infertility, Menopause, Ovarian failure, Pelvic inflammatory disease, Polycystic ovary syndrome, Pre-menstrual syndrome, Prolapse, Amenorrhea, Dysmenorrhea, Pelvic pai, Vaginitis, plus other gynecological indications.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gynecology technologies and products.

Global Gynecology Partnering 2010 to 2020 includes:

Available deals and contracts are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in Gynecology dealmaking2.1. Introduction2.2. Gynecology partnering over the years2.3. Gynecology partnering by deal type2.4. Gynecology partnering by industry sector2.5. Gynecology partnering by stage of development2.6. Gynecology partnering by technology type2.7. Gynecology partnering by therapeutic indication

Chapter 3 Financial deal terms for Gynecology partnering3.1. Introduction3.2. Disclosed financials terms for Gynecology partnering3.3. Gynecology partnering headline values3.4. Gynecology deal upfront payments3.5. Gynecology deal milestone payments3.6. Gynecology royalty rates

Chapter 4 Leading Gynecology deals and dealmakers4.1. Introduction4.2. Most active in Gynecology partnering4.3. List of most active dealmakers in Gynecology4.4. Top Gynecology deals by value

Chapter 5 Gynecology contract document directory5.1. Introduction5.2. Gynecology partnering deals where contract document available

Chapter 6 Gynecology dealmaking by therapeutic target6.1. Introduction6.2. Deals by Gynecology therapeutic target

AppendicesAppendix 1 Directory of Gynecology deals by company A-Z 2010 to 2020Appendix 2 Directory of Gynecology deals by deal type 2010 to 2020Appendix 3 Directory of Gynecology deals by stage of development 2010 to 2020Appendix 4 Directory of Gynecology deals by technology type 2010 to 2020

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/9ex5qc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Continue reading here:
Global Gynecology Partnering Report 2020: Access Deals Signed Between the World's Leading Pharmaceutical and Biotechnology Companies Since 2010 -...

Are Options Traders Betting on a Big Move in in Vir Biotechnology (VIR) Stock? – Yahoo Finance

TipRanks

Semiconductors are one of the modern worlds essential industries, making possible so much of what we rely on or take for granted: internet access, high-speed computers with high-speed memory, even the thermostats that control our air conditioning there isnt much, tech-wise, that doesnt use semiconductor chips.With the end of 2020 in sight, its time for the annual ritual of evaluating the equities for the New Year. Wells Fargo analyst Aaron Rakers has cast his eye on the chip industry, tagging several companies as likely gainers next year.The analyst sees several factors combining to boost demand for chips in 2021, including cloud demand, new gaming consoles, and a market resolution to the future of the PC segment. Overall, however, Rakers expects that memory chips and 5G enabled chips will emerge as the drivers of the industry next year. The analyst expects that semiconductor companies, as a group, will see between 10% and 12% growth over the next 12 months.Thats an industry-wide average, however. According to Raker, some chip companies will show significantly higher growth, on the order of 30% to 40% in year ahead. We can look at those companies, along with the latest TipRanks data, to find out what makes these particular chip makers so compelling.Micron Technology (MU)Among the leading chip makers, Micron has staked out a position in the memory segment. The company has seen its market cap expand to $78 billion this year, as shares have appreciated 32% year-to-date. The surge comes on a product line heaving on computer data storage, DRAM, and flash storage.Look back at 2020, Micron has seen revenues increase each quarter, from $4.8 billion in Q1 to $5.4 billion in Q2 to $6.1 billion in Q3. Earnings came in at 87 cents per share, up from 71 cents in Q2 and 36 cents in Q1.The calendar third quarter was Microns 4QFY20, and the full fiscal year showed a decline due attributed to the COVID pandemic. Revenue came in at $21.44 billion, down 8.4% year-over-year, and operating cash flow fell to $8.31 billion from $13.19 billion in FY19. During this past quarter, Microns 1QFY21, the company announced the release of the worlds first 176-layer 3D NAND chip. The new chip promises higher density and faster performance in flash memory, and the architecture is described as a radical breakthrough. The layer count is 40% higher than competing chips.Looking ahead, Micron has updated its F1Q21 guidance, predicting total revenue of $5.7 billion to $5.75 billion. This is a 10% increase from the previous guidance.Wells Fargo's Aaron Rakers calls Micron his top semiconductor idea for 2021. He points out a deepening positive view on the memory, and in particular the DRAM industry. DRAM accounts for approximately two-thirds of Microns revenue and over 80% of the companys bottom-line profits. In addition, Rakers notes Microns technology execution 1Znm DRAM leadership; recently outlined 1nm ramp into 2021, as well as Microns move to 176-Layer 2nd -gen Replacement Gate 3D NAND to drive improved cost curve. We would also highlight Microns execution on graphics memory (e.g., GDDR6X), Multi-Chip Packages (MCPs), and High-Bandwidth Memory (e.g., HBME2) as positives.In line with these comments, Rakers rates Micron shares a Buy, along with a $100 price target. This figure suggests room for 41% growth in 2021. (To watch Rakers track record, click here)Micron has 24 recent reviews on record, breaking down to 19 Buys, 4 Holds, and 1 Sell, and giving the stock a Strong Buy from the analyst consensus. Shares are priced at $70.96, and recent appreciation has pushed them almost to the $74.30 average price target. But as Rakers outlook suggests, there may be more than just 4.5% upside available here. (See MU stock analysis on TipRanks)Advanced Micro Devices (AMD)With $6.5 billion in total sales last year, and a market cap of $110.7 billion, AMD is a giant company but it doesnt even crack the top five of the worlds largest chip makers. Still, AMD has a solid position in the industry, and its x86 processors provide stiff competition for market-leading Intel (INTC). AMD shares have shown solid growth this year, and are up 101% as 2020 comes to a close.The share growth rides on the back of steady revenue gains since the corona crisis peaked in Q1. AMDs Q3 top line came in at $2.8 billion, up 55% from the $1.8 billion recorded in the year-ago quarter and beating the forecast by 10%. Earnings, at 37 cents per share, were up 220% year-over-year. The company credited the growth to solid results in the PC, gaming, and data center product lines, and boasted that it was the fourth consecutive quarter with >25% yoy revenue growth.AMD announced last month a new product for the scientific research market, the Instinct MI100 accelerator. The new chip is billed as the worlds fasted HPC GPU, and the first such x86 server to exceed 10 teraflops performance.Covering AMD for Wells Fargo, Rakers wrote: We remain positive on AMDs competitive positioning for continued sustained gradual share gains in PCs We also believe AMDs deepening data center GPU strategy with new Instinct MI100 GPUs and the release of RoCM 4.0 software platform could become increasingly visible as we move through 2021. AMDs roadmap execution would remain an important focus 7nm+ Ryzen 4000-series, new RDNA Radeon Instinct data center GPUs (MI100 / MI120), and the 3 rd -gen 7nm+ EPYC Milan CPUsRakers stance supports his Buy rating, and his $120 price target implies a 30% one-year upside to the stock.The Moderate Buy analyst consensus view on AMD reflects some residual Wall Street caution. The stocks 20 recent reviews include 13 Buys, 6 Holds, and 1 Sell. AMD shares are selling for $91.64, and like Micron, their recent appreciation has closed the gap with the $94.71 average price target. (See AMD stock analysis on TipRanks)Western Digital Corporation (WDC)Closing out the Wells Fargo picks on this list is Western Digital, a designer and manufacturer of memory systems. The companys products include hard disk drives, solid state drives, data center platforms, embedded flash drives, and portable storage including memory cards and USB thumb drives. WDC has had a tough year in 2020, with shares down 19% year-to-date. Still, the stock has seen gains in November and December, on the heels of what was seen as a strong fiscal 1Q21 report.That earnings report showed $3.9 billion in revenue, which was down 3% year-over-year, but the EPS net loss, at 19 cents, was a tremendous yoy improvement from the 93-cent net loss in the year-ago quarter. The earnings improvement, which beat the forecast by 20%, was key for investors, and the stock is up 30% since the quarterly report. The company also generated a solid cash flow in the quarter, with cash from operations growing 111% sequentially.Wells Fargos Rakers acknowledges WDCs difficulties in 2020, but even so, he believes that this is a stock which is worth the risk.Western Digital has been our toughest constructive call of 2020 and while we believe calling a bottom in NAND Flash (mid/2H2021?) remains difficult and WDs execution in enterprise SSDs will remain choppy, our SOTP analysis leaves us to continue to believe that shares present a compelling risk / reward. We continue to believe that Western Digital can drive to a ~$7/sh.+ mid-cycle EPS story; however, we continue to think a key driver of this fundamental upside will not only be a recovery in the NAND Flash business, coupled with WDs ability to see improved execution in enterprise SSDs, but also a continued view that WDs HDD gross margin can return to a sustainable 30%+ level, Rakers opined.To this end, Rakers rates WDC a Buy along with a $65 price target. Should the target be met, investors could pocket gains of 29% over the next months Where does the rest of the Street side on this computer-storage maker? It appears mostly bullish, as TipRanks analytics demonstrate WDC as a Buy. Out of 11 analysts tracked in the last 3 months, 7 are bullish, while 4 remain sidelined. With a return potential of 9%, the stocks consensus target price stands at $54.44. (See WDC stock analysis on TipRanks)To find good ideas for tech stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Here is the original post:
Are Options Traders Betting on a Big Move in in Vir Biotechnology (VIR) Stock? - Yahoo Finance

Pharmaceutical And Biotechnology Machines Market Thriving Impulsive Hike With Key Players – LionLowdown

The Pharmaceutical And Biotechnology Machines Marketreport enlists essential and realistic data with regards to the market situation. The current situation of the Pharmaceutical And Biotechnology Machines market, alongside its preceding overall performance as properly as future scope are included in the report. It demonstrates a quick summary of industry facts and the key nomenclature of the market. The report has highlights, regularly occurring performers, from the global market together with their contribution to the market to decide their growth inside the estimated time.

Furthermore, The report covers key strategic points regarding developments in the market which include acquisitions & mergers, agreements, partnerships, new type launches, research & development, collaborations & joint ventures, regional growth of predominant contributors concerned in the Pharmaceutical And Biotechnology Machines market on a global and regional basis.

Get Sample Report + All Related Graphs & Charts: https://www.stratagemmarketinsights.com/sample/19841

It Furnishes detailed information on the factors that will restrain the growth of Pharmaceutical And Biotechnology Machines manufacturers: Air Liquide, Linde Healthcare, Praxair, Air Products, Taiyo Nippon Sanso, Matheson Gas, Atlas Copco AB, Messer Group, SOL Group, Norco, Sicgil Limited, Shenzhen Gaofa, Shenwei Medical, Beijing Orient, Nanning Lantian

Pharmaceutical And Biotechnology Machines Market COVID-19 Impact Analysis:

As the world is still dealing with the COVID-19 situation, many of the countries have slowly started to revive their economic situation by starting their trade and businesses. There has been an enormous loss in these few months both in terms of economy and human lives. As the WHO has already suggested that there are very less chances that the virus will completely go, hence we will have started living with it. Many of the drug companies are getting a positive response to their COVID-19 vaccines, but there is still time for their availability in the global market.

Research Methodology:

The process of market research at SMI is iterative in nature and generally follows the following path. Information from secondary is used to construct records models, in addition, the consequences got from data models are validated from essential participants. Then cycle repeats where, in accordance with inputs from important participants, additional secondary research is completed and new information is once more integrated into the data model. The process continues until the favored degree of facts is no longer generated.

To calculate the Pharmaceutical And Biotechnology Machines market size, the report considers the revenue generated from the sales of the market providers. The revenue generated from the sales of the market is calculated through essential and secondary research. The key players working in the market throughout the globe are recognized via secondary research and a corresponding detailed analysis of the top vendors in the market is done. The market size calculation additionally consists of clinical trial phase segmentation that decided the usage of secondary sources and verified thru primary sources.

The report covers exhaustive analysis on:

Regional analysis includes:

Report Highlights:

Key Question and Answers in the Study:

Get assured Discount on this Report (UsePrompocodeCHRISTMAS25):https://www.stratagemmarketinsights.com/discount/19841

[**Note: To avail of this offer Specify this Promo code in precise requirement.]

Contact Us:

Mr. ShahStratagem Market InsightsTel:USA +1-415-871-0703JAPAN +81-50-5539-1737UK +44-203-289-4040Email: [emailprotected]

Explore BySJ

Link:
Pharmaceutical And Biotechnology Machines Market Thriving Impulsive Hike With Key Players - LionLowdown